Dealing by Person Closely Associated
November 01, 2016 11:30 ET | AstraZeneca PLC
1 November 2016 15:30 Transaction by Person Closely Associated with a Person Discharging Managerial Responsibilities Disclosure under Articles 19(3) and 19(6) of the EU Market Abuse Regulation On...
AZ completes US Aralez agreement for Toprol-XL
October 31, 2016 10:19 ET | AstraZeneca PLC
31 October 2016 13:45 ASTRAZENECA COMPLETES AGREEMENT WITH ARALEZ FOR BETA-BLOCKER MEDICINE TOPROL-XL IN THE US AstraZeneca today announced the completion of...
AstraZeneca Head and Neck Cancer Trials
October 27, 2016 12:02 ET | AstraZeneca PLC
27 October 2016 16:50 ASTRAZENECA HEAD AND NECK CANCER TRIALS Following the recent update on clinicaltrials.gov, AstraZeneca confirms that the US FDA has placed a partial clinical hold on the...
Positive results in AstraZeneca Lynparza trial
October 26, 2016 02:00 ET | AstraZeneca PLC
This announcement contains inside information 26 October 2016 07:00 LYNPARZA PHASE III SOLO-2 TRIAL SHOWS SIGNIFICANT PROGRESSION-FREE SURVIVAL BENEFIT Trial studied Lynparza as maintenance...
FDA ACCEPTS FOR REVIEW NEW DRUG APPLICATION FOR SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) FOR THE TREATMENT OF HYPERKALAEMIA
October 18, 2016 02:00 ET | AstraZeneca PLC
18 October 2016 [07:00] AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a complete re-submission of a New Drug Application (NDA) for sodium zirconium...
AZ agreement with Aralez for Toprol-XL in US
October 04, 2016 02:05 ET | AstraZeneca PLC
This announcement contains inside information 4 October 2016 07:05 ASTRAZENECA ENTERS AGREEMENT WITH ARALEZ FOR BETA-BLOCKER MEDICINE TOPROL-XL IN THE US AstraZeneca today announced that it has...
AstraZeneca reports top-line EUCLID results in PAD
October 04, 2016 02:00 ET | AstraZeneca PLC
This announcement contains inside information 04 October 2016 07:00 ASTRAZENECA REPORTS TOP-LINE RESULTS FROM THE BRILINTA EUCLID TRIAL IN PATIENTS WITH PERIPHERAL ARTERY DISEASE Brilinta did not...
Total Voting Rights
October 03, 2016 10:00 ET | AstraZeneca PLC
3 October 2016 15:00 Transparency Directive Voting Rights and Capital The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule...
ASTRAZENECA PLC ANNOUNCES MEDIMMUNE OUT-LICENSES POTENTIAL MEDICINE FOR INFLAMMATORY DISEASES TO ALLERGAN
October 03, 2016 02:00 ET | AstraZeneca PLC
This announcement contains inside information 03 October 2016 07:00 AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a licensing...
CHANGE TO ASTRAZENECA BOARD OF DIRECTORS
September 28, 2016 02:00 ET | AstraZeneca PLC
28 September 2016 07:00 CHANGE TO ASTRAZENECA BOARD OF DIRECTORS AstraZeneca today announced that Dr Cornelia (Cori) Bargmann, a Non-Executive Director, will step down from the Board of AstraZeneca...